Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 73,100 shares, a growth of 28.7% from the June 15th total of 56,800 shares. Based on an average trading volume of 118,500 shares, the short-interest ratio is presently 0.6 days. Currently, 0.7% of the company’s shares are short sold.
Conduit Pharmaceuticals Stock Down 8.6 %
Shares of Conduit Pharmaceuticals stock traded down $0.02 during trading hours on Monday, reaching $0.24. 3,241,981 shares of the company were exchanged, compared to its average volume of 164,488. Conduit Pharmaceuticals has a 1 year low of $0.21 and a 1 year high of $25.00. The stock’s fifty day moving average is $2.04 and its 200 day moving average is $2.83.
Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.05) earnings per share for the quarter.
Conduit Pharmaceuticals Company Profile
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Further Reading
- Five stocks we like better than Conduit Pharmaceuticals
- Most Volatile Stocks, What Investors Need to Know
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- Upcoming IPO Stock Lockup Period, Explained
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- Insider Trades May Not Tell You What You Think
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.